article Open AccessTop 1% cited
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
American Journal of Kidney Diseases · 2019 · Vol. 75(1) · pp. 84–104
Andrew S. Levey✉(Tufts Medical Center)Ron T. Gansevoort(University Medical Center Groningen)Josef Coresh(Johns Hopkins University)Lesley A. Inker(Tufts Medical Center)Hiddo J.L. Heerspink(University Medical Center Groningen)Morgan E. Grams(Johns Hopkins University)Tom Greene(University of Utah)Hocine Tighiouart(Tufts University)Kunihiro Matsushita(Johns Hopkins University)Shoshana H. Ballew(Johns Hopkins University)Yingying Sang(Johns Hopkins University)Edward F. Vonesh(Northwestern University)Jian Ying(University of Utah)Tom Manley(National Kidney Foundation)Dick de Zeeuw(University Medical Center Groningen)Kai‐Uwe Eckardt(Charité - Universitätsmedizin Berlin)Adeera Levin(University of British Columbia)Vlado Perkovic(UNSW Sydney)Luxia Zhang(Peking University)Kerry Willis(National Kidney Foundation)
Chronic Kidney Disease and DiabetesRenal Diseases and GlomerulopathiesDialysis and Renal Disease ManagementMedicineRenal functionKidney diseaseAlbuminuriaClinical trialObservational studyHazard ratioCreatinineInternal medicineIntensive care medicine
MeSH terms
AlbuminuriaBayes TheoremCreatinineEuropeGlomerular Filtration RateHumansKidney Failure, ChronicUnited StatesUnited States Food and Drug AdministrationBiomarkersDrug ApprovalDisease ProgressionRenal Insufficiency, Chronic
Funding
- AstraZeneca
- Bayer
- Merck
- Novartis
- Gilead Sciences
- Alexion Pharmaceuticals
- AbbVie
- Tufts Medical Center
- Boehringer Ingelheim
- Ironwood Pharmaceuticals, Incorporated
- Astellas Pharma Canada
- Kyowa Hakko Kirin
- Novo Nordisk
- Siemens
- Servier
- Ipsen
- National Institutes of Health
- Sanofi Genzyme
- Relypsa
Citations
545
FWCI
31.32
field-weighted impact
References
52
Percentile
100%
vs. same field & year
Citations per year
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Kidney International · 2021 · 2,277 citations
References
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Clinical Pharmacology & Therapeutics · 2001 · 6,574 citations
Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system
Journal of Hypertension · 2007 · 411 citations
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
Kidney International · 2010 · 2,313 citations
GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
American Journal of Kidney Diseases · 2014 · 577 citations
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
The Lancet · 2005 · 6,802 citations
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation
American Journal of Physiology-Renal Physiology · 1981 · 1,678 citations
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Kidney International · 2024 · 6,803 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.